#USA #Cranford #CTCL #Citius Oncology #LYMPHIR™

Citius Oncology Celebrates Positive Progress with LYMPHIR™ Launch

Citius Oncology, Inc. has provided a promising commercial update on its recently launched drug LYMPHIR™ (denileukin diftitox-cxdl), aimed at treating cutaneous T-cell lymphoma (CTCL). This news highlights a robust early adoption rate among leading cancer centers, and an encouraging growth in market access as well as clinical studies emphasizing LYMPHIR's potential.

Early Commercial Indicators

The company has reported exciting early metrics indicating a successful launch trajectory for LYMPHIR. Key highlights include:

• - Strong Order Growth: There has been a noteworthy sequential growth in orders from target institutions since the launch, with many accounts already making repeat orders.
• - High Institutional Uptake: Approximately 83% of target accounts have initiated or are actively progressing their formulary inclusion of LYMPHIR.
• - Market Access Progress: Citius has secured coverage from around 135 health plans, which represents roughly 80% of covered lives, thus facilitating broad access to patients in need.
• - Positive Feedback: There have been no reports of reimbursement denials or prior authorization barriers, which is crucial for ensuring patient access.
• - Increasing Demand for Education: As doctors seek to better understand LYMPHIR’s applications, there is a rising demand for in-services and clinical education.
• - Initial Community Penetration: Patients are beginning to transition from large cancer centers to community infusion centers, indicating potential growth in broader treatment settings.
• - Active Commercial Buildout: A field sales team is being onboarded to enhance market penetration further.

CEO Leonard Mazur expressed optimism regarding these developments, noting that as more institutions complete their formulary inclusion processes, the prescribing activity is expected to grow, particularly in community settings. The anticipated integration of LYMPHIR in CTCL treatment regimens and potential combination therapies in other cancer treatments is also encouraging.

Clinical Development Expanding

In conjunction with commercial progress, Citius Oncology is enhancing the clinical profile of LYMPHIR through partnerships with leading academic institutions. Notable efforts include:

• - At the University of Minnesota, an investigator-sponsored study is currently evaluating LYMPHIR in conjunction with CAR-T therapies for relapsed or refractory diffuse large B-cell lymphoma, demonstrating promising preliminary results at a recent medical meeting.
• - Collaborations at UPMC have led to the completion of a Phase I study assessing LYMPHIR in combination with pembrolizumab for solid tumors, with encouraging results expected to be presented at an upcoming oncology conference.

These academic collaborations support a strategy to evaluate LYMPHIR not only for CTCL but also as a component in immuno-oncology settings, expanding its potential applications.

Conclusion

Citius Oncology is making significant strides with LYMPHIR™ since its U.S. launch in December 2025, navigating a landscape of promising market dynamics and clinical advancements. The solid initial uptake among cancer centers and streamlining access through reimbursement channels underscore the potential for LYMPHIR to address an expansive and underserved market in oncology care. As the company continues to foster clinical partnerships and extend its reach into community settings, the future looks promising for both LYMPHIR and its role within the broader oncology treatment paradigm.

For more information about LYMPHIR and Citius Oncology, visit www.citiusonc.com.